RxDoctor Payments Data

Abdul Khan, MD

Interventional Cardiology · Las Cruces, NMNPI 1528449576

Payments from drug & device makers

What this record shows

28 manufacturers reported payments, led by Abbott at 30.4% of the total. 2025 is the largest year on record at $8,942, 2.7 times the $3,330 reported in 2022.

$22,806in general payments, 2019–2025

Across 227 payments — averaging $100.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Penumbra, Inc.$5K
  • Inari Medical, Inc.$3K
  • Medtronic$3K
  • Abiomed$2K
  • Philips North America LLC$2K
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$13,22158%
  • Food & beverage$9,58642%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,806 in reported general payments places this provider in the 85th percentile of 25 interventional cardiology providers in New Mexico.

See all interventional cardiology providers in New Mexico

Medicare billing

Part B allowed, 2024
$181,294
Medicare patients
840
Services billed
2,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$273,257
EntrestoSacubitril/Valsartan89$125,291
Repatha SureclickEvolocumab60$65,448
XareltoRivaroxaban32$47,042
BrilintaTicagrelor58$44,820
JardianceEmpagliflozin14$23,263
FarxigaDapagliflozin Propanediol12$20,196
Ranolazine ErRanolazine53$6,857
Metoprolol Succinate474$5,587
Rosuvastatin Calcium409$4,872
ClopidogrelClopidogrel Bisulfate260$3,210
Isosorbide Mononitrate ErIsosorbide Mononitrate236$2,626
Atorvastatin Calcium206$2,098
Nitroglycerin146$1,621
Amiodarone Hcl54$1,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$293$125,29189 claims
AstraZenecaBrilinta, Farxiga$33$65,01670 claims
Johnson & JohnsonXarelto$54$47,04232 claims
Boehringer IngelheimJardiance$120$23,26314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 25 interventional cardiology providers in New Mexico.

Other interventional cardiology in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →